Cervical Cancer
Fluorouracil plus radiotherapy did not improve cervix cancer over cisplatin
Published in Women's Health Weekly, February 9th, 2006
"Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer; the optimal chemotherapy regimen is not yet defined. This trial was designed to compare the outcome of PVI FU with standard weekly cisplatin and concurrent radiation therapy (RT). Patients with stage IIB, IIIB, and IVA cervical cancer with clinically negative aortic nodes were eligible," scientists in the United States reported.
"Pelvic FIT dose was 45 Gy with a parametrial boost to involved sides of 5.4 to 9 Gy,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Heart Disease
Coronary heart disease is associated with women exposed to ambient particulate matter - Injury Prevention
Female crash test dummy may improve traffic safety protection for women - Ovarian Cancer Prevention
Tea consumption results in a dose-response reduction in risk for ovarian cancer - Rheumatoid Arthritis
Women with rheumatoid arthritis report greater disability in functional capacity than men - Weight Loss
Dietary restrictions appear more beneficial than exercise for weight loss - Allergy & Immunology
Immunoglobulin rBet v1 G4-antibodies may modulate allergic rhinoconjunctivitis - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
